1887

Abstract

Tuberculosis (TB) remains a major threat to human health worldwide. The increasing incidence of non-tuberculous mycobacterial infections and particularly those produced by Mycobacterium avium has emphasized the need to develop new drugs. Additionally, high levels of natural drug resistance in non-tuberculous mycobacteria (NTM) and the emergence of multidrug-resistant (MDR) TB is of great concern. Antimicrobial peptides (AMPs) are antibiotics with broad-spectrum antimicrobial activity. The objective was to assess the activity of AMPs against Mycobacterium tuberculosis and M. avium clinical isolates. MICs were determined using microtitre plates and the resazurin assay. Mastoparan and melittin showed the greatest activity against M. tuberculosis , while indolicidin had the lowest MIC against M. avium . In conclusion, AMPs could be alternatives for the treatment of mycobacterial infections. Further investigation of AMPs' activity in combination and associated with conventional antibiotics and their loading into drug-delivery systems could lead to their use in clinical practice.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000912
2018-12-20
2019-10-21
Loading full text...

Full text loading...

References

  1. World Health Organization Global Tuberculosis Report 2017 Geneva, Switzerland: WHO; 2017;http://www.who.int/tb/publications/global accessed 24 January 2018
    [Google Scholar]
  2. World Health Organization Surveillance of Drug Resistance in Tuberculosis: Guidelines, 5th ed. Geneva, Switzerland: WHO; 2015
    [Google Scholar]
  3. Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012;25:545–582 [CrossRef][PubMed]
    [Google Scholar]
  4. Vila-Farrés X, Giralt E, Vila J. Update of peptides with antibacterial activity. Curr Med Chem 2012;19:6188–6198 [CrossRef][PubMed]
    [Google Scholar]
  5. Giacometti A, Cirioni O, Barchiesi F, del Prete MS, Scalise G. Antimicrobial activity of polycationic peptides. Peptides 1999;20:1265–1273 [CrossRef][PubMed]
    [Google Scholar]
  6. Yan H, Hancock RE. Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob Agents Chemother 2001;45:1558–1560 [CrossRef][PubMed]
    [Google Scholar]
  7. Silva JP, Appelberg R, Gama FM. Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv 2016;34:924–940 [CrossRef][PubMed]
    [Google Scholar]
  8. Zhao X, Wu H, Lu H, Li G, Huang Q. LAMP: A Database Linking Antimicrobial Peptides. PLoS One 2013;8:e66557 [CrossRef][PubMed]
    [Google Scholar]
  9. Abedinzadeh M, Gaeini M, Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis. J Antimicrob Chemother 2015;70:1285–1289 [CrossRef][PubMed]
    [Google Scholar]
  10. Giacometti A, Cirioni O, del Prete MS, Barchiesi F, Paggi AM et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2000;46:807–810 [CrossRef][PubMed]
    [Google Scholar]
  11. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C et al. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 2003;24:1315–1318 [CrossRef][PubMed]
    [Google Scholar]
  12. Vila-Farres X, Garcia de La Maria C, López-Rojas R, Pachón J, Giralt E et al. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2012;18:383–387 [CrossRef][PubMed]
    [Google Scholar]
  13. Palomino JC, Portaels F. Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur J Clin Microbiol Infect Dis 1999;18:380–383 [CrossRef][PubMed]
    [Google Scholar]
  14. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system. J Antimicrob Chemother 2016;71:1532–1539 [CrossRef][PubMed]
    [Google Scholar]
  15. Gutsmann T. Interaction between antimicrobial peptides and mycobacteria. Biochim Biophys Acta 2016;1858:1034–1043 [CrossRef][PubMed]
    [Google Scholar]
  16. Sharma S, Verma I, Khuller GK. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000;16:112–117 [CrossRef][PubMed]
    [Google Scholar]
  17. Ogata K, Linzer BA, Zuberi RI, Ganz T, Lehrer RI et al. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992;60:4720–4735[PubMed]
    [Google Scholar]
  18. Grassi L, Maisetta G, Esin S, Batoni G. Combination strategies to enhance the efficacy of antimicrobial peptides against bacterial biofilms. Front Microbiol 2017;8:2409 [CrossRef][PubMed]
    [Google Scholar]
  19. Sharma A, Sharma S, Khuller GK, Kanwar AJ. In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents 2009;34:226–230 [CrossRef][PubMed]
    [Google Scholar]
  20. Yu G, Baeder DY, Regoes RR, Rolff J. Combination effects of antimicrobial peptides. Antimicrob Agents Chemother 2016;60:1717–1724 [CrossRef][PubMed]
    [Google Scholar]
  21. Li DG, Ren ZX. Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease. Braz J Med Biol Res 2017;50:e6188 [CrossRef][PubMed]
    [Google Scholar]
  22. Fu LM. The potential of human neutrophil peptides in tuberculosis therapy. Int J Tuberc Lung Dis 2003;7:1027–1032[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000912
Loading
/content/journal/jmm/10.1099/jmm.0.000912
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error